387 related articles for article (PubMed ID: 24460800)
1. Residual macrovascular risk in 2013: what have we learned?
Fruchart JC; Davignon J; Hermans MP; Al-Rubeaan K; Amarenco P; Assmann G; Barter P; Betteridge J; Bruckert E; Cuevas A; Farnier M; Ferrannini E; Fioretto P; Genest J; Ginsberg HN; Gotto AM; Hu D; Kadowaki T; Kodama T; Krempf M; Matsuzawa Y; Núñez-Cortés JM; Monfil CC; Ogawa H; Plutzky J; Rader DJ; Sadikot S; Santos RD; Shlyakhto E; Sritara P; Sy R; Tall A; Tan CE; Tokgözoğlu L; Toth PP; Valensi P; Wanner C; Zambon A; Zhu J; Zimmet P;
Cardiovasc Diabetol; 2014 Jan; 13():26. PubMed ID: 24460800
[TBL] [Abstract][Full Text] [Related]
2. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
[TBL] [Abstract][Full Text] [Related]
3. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
4. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Fruchart JC; Sacks FM; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P;
Diab Vasc Dis Res; 2008 Nov; 5(4):319-35. PubMed ID: 18958843
[TBL] [Abstract][Full Text] [Related]
5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
6. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
7. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
8. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
11. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
12. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia.
Fruchart JC
Cardiovasc Diabetol; 2017 Oct; 16(1):124. PubMed ID: 28978316
[TBL] [Abstract][Full Text] [Related]
13. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
14. Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408799
[TBL] [Abstract][Full Text] [Related]
15. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
16. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Plutzky J; Ponte-Negretti CI; Pradhan A; Ray KK; Reiner Ž; Ridker PM; Ruscica M; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoğlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yamashita S; Yokote K; Zambon A; Libby P
Cardiovasc Diabetol; 2019 Jun; 18(1):71. PubMed ID: 31164165
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia in diabetes.
Kalra S; Raizada N
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S80-S82. PubMed ID: 37956957
[TBL] [Abstract][Full Text] [Related]
20. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
